Chronic lymphocytic leukemia (CLL) has long been treated with chemotherapy, but that’s no longer the only option. Zanubrutinib is one of the latest CLL drugs, a targeted treatment that blocks the protein CLL cells need to grow and is also designed for oral administration. For the approximately 22,760 Americans likely to be diagnosed with CLL in 2026, it might lead to a different safety and administration profile compared to chemotherapy. This guide discusses some of the changes in the treatment of CLL and the significant role that zanubrutinib has had in this change.
Key Takeaways
- CLL is the most common leukemia of adults in the United States, usually occurring around age 70 and many people may not need treatment right away.
- The National Comprehensive Cancer Network (NCCN) recommends zanubrutinib as a preferred BTK inhibitor therapy for CLL/SLL, both pre- and post-treatment, and with or without presence of del(17p) or TP53 mutation.
- Acalabrutinib and venetoclax were FDA approved for the treatment of newly diagnosed CLL patients in February 2026 as the first combination treatment in which both drugs are administered orally and the treatment lasts for a set duration.
- A definite end date to treatment can enhance quality of life, due to fixed duration treatment rather than taking medication daily.
- Genetic markers (such as del(17p) and TP53 status) dictate treatment choice and it should be determined with a hematologist/oncologist.
Understand the Nature of CLL and Why Treatment Has Changed
CLL is a very slow-growing white blood cell cancer, and it’s the most common form of leukemia in adults. When treatment does become necessary, the goal has always been the same: control the disease while protecting quality of life. What’s different now is how doctors get there. A decade ago, that meant chemotherapy regimens like FCR (fludarabine, cyclophosphamide, and rituximab), which kill fast-growing cells throughout the body and often bring fatigue, infections, and other side effects that are hard on older patients. Today, targeted drugs can do the same job with a more precise approach.
The Transition From Chemotherapy to Targeted Therapy for CLL – A New Approach to the Disease
The first step to understanding the latest CLL drugs is understanding this change: targeted drugs block the signals that CLL cells need to survive, and do not damage healthy cells in the process. Three drug classes make up the backbone of modern CLL care: BTK inhibitors, BCL-2 inhibitors, and PI3K inhibitors, often combined with CD20 antibodies such as obinutuzumab or rituximab. This precision is a big part of why the newest treatment options have such a different side-effect profile than older chemotherapy regimens, and why more patients can take their medication as a pill at home instead of visiting an infusion clinic.
BTK Inhibitors: Ibrutinib, Acalabrutinib, Zanubrutinib and Pirtobrutinib
CLL cells use the protein Bruton’s tyrosine kinase to continue to grow, and treatments that inhibit this protein have significantly changed the CLL treatment landscape. Ibrutinib was the first BTK inhibitor available to patients and expanded treatment options for patients who had been previously given a poor prognosis with chemotherapy, due to the presence of the del(17p) genetic mutation. In this regard, acalabrutinib and zanubrutinib have taken a step in this direction by demonstrating more specificity and less heart rhythm toxicity and bleeding.
Zanubrutinib works by shutting down BTK signaling for a full 24 hours, and it blocks up to 100% of BTK in blood cells and 94% to 100% in lymph nodes at its standard dose. In two head-to-head trials, it showed improved efficacy outcomes than a bendamustine-rituximab regimen in previously untreated patients, and it showed improved results than ibrutinib in previously treated patients – with far fewer people stopping treatment because of side effects, 8% compared with 14%, and 15% compared with 22%.
The National Comprehensive Cancer Network (NCCN) guidelines now recommend Zanubrutinib as a standard treatment choice for both first- and second-line CLL, with or without mutation. A newer drug, pirtobrutinib, binds to the BTK only temporarily, not permanently, so it continues to function when CLL has stopped responding to a previous BTK inhibitor.
Other Targeted Options Still in the Mix
Venetoclax targets a different vulnerability by blocking BCL-2, a protein that helps CLL cells resist normal cell death, and it’s often paired with a BTK inhibitor for a fixed-duration course rather than daily treatment for life. In fact, the FDA approved acalabrutinib plus venetoclax together in February 2026 as the first all-oral, fixed-duration combination for newly diagnosed CLL patients without del(17p) or TP53 mutations, based on strong results from the phase 3 AMPLIFY trial – patients on the combination had a 76.5% chance of being progression-free at three years, compared with 66.5% on standard chemoimmunotherapy.
PI3K inhibitors like idelalisib and duvelisib target a different pathway but come with more serious side effects, such as liver problems and heavy diarrhea, so they’re generally reserved for later lines of treatment. CD20 antibodies are frequently combined with other therapies to boost response rates, especially in older or frailer patients who may not tolerate more aggressive treatment.
How These Advances Impact Patients and Caregivers
The effects of the latest CLL drugs mean that for a newly diagnosed CLL patient, the treatment plan might mean taking pills at home instead of infusions at an infusion centre, having a treatment plan that ends on a specific date rather than one that continues indefinitely, and a treatment plan based on genetic markers instead of a one-size-fits-all treatment. Caregivers benefit too; fewer clinic visits and a defined treatment timeline can make it easier to plan around work, travel, and everyday life instead of building a schedule around ongoing infusions.
None of this replaces a conversation with a hematologist/oncologist, who can weigh a patient’s mutation profile, age, other health conditions, and personal preferences before recommending a path forward. Patients starting any of these targeted therapies will still need regular blood work and monitoring, since side effects like low blood counts, infections, and heart rhythm changes can occur even with the newer, better-tolerated drugs. Bringing a full medication list and asking directly about mutation testing, dosing schedules, and what to expect during the first few months of treatment can make that first appointment far more productive.
Talking With the Care Team About the Latest CLL Drugs
The range of choices available today, and the pace at which new data keeps arriving, marks a genuine shift from where CLL treatment stood even a decade ago. Patients who were told years ago that their only option was chemotherapy may find that a targeted, fixed-duration regimen is now an option that may be considered based on various factors.
Medical disclaimer: This article is for informational purposes only and isn’t a substitute for medical advice – anyone diagnosed with CLL should consult with the healthcare professionals team about appropriate treatment options.